Despite significant technological advancements in drug discovery, clinical trial failure rates have remained stubbornly stable because the pharmaceutical industry continuously pushes boundaries to tackle increasingly complex diseases. Readers note that this persistent equilibrium reflects shifting criteria for medical success, the elimination of easy targets, and the heavy career toll on scientists working to translate early research into human outcomes.